Global Immuno Oncology Market

Immuno Oncology Comprehensive Study by Type (Cytokines,, Bispecific Antibodies, Cancer Vaccines, Cell Therapies, Immune Checkpoint Inhibitor, Oncolytic Viruses), End Users (Hospitals, Clinics, Others), Therapy Type (Checkpoint Inhibitors & Immunomodulators, Cancer Vaccines, Oncolytic Virus, Others), Therapy Area (Lung Cancer, Bladder Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Liver Cancer, Other Cancers) Players and Region - Global Market Outlook to 2030

Immuno Oncology Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 20.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Immuno Oncology Market Scope
Immuno-oncology therapy can provide more durable clinical outcomes than traditional therapies such as chemotherapy and radiotherapy and in some cases contribute to complete tumor regression. Immuno-oncology therapies also pose a less detrimental impact on patients’ quality of life due to a lower incidence of serious adverse events. Moreover, the rising number of cancer cases worldwide is one of the major factors aiding the growth of the market. Amid the lockdown across different regions, patients suffering from cancer were expected to be at a higher risk, due to the COVID-19 which has also made it difficult to manage the cancer care delivery system. So the requirement of oncologists to be more attentive to detect coronavirus infection early, as any type of advanced cancer is at much higher risk for unfavorable outcomes for the patients. Moreover, due to the lockdown across different countries, the patients were not able to travel from one place to another for their treatment which has led to a slight disparity in cancer care across different regions. Therefore, the global immuno-oncology market is expected to witness a slight decline in its y-o-y growth during the FY-2020 compared to FY 2019 which is again expected to regain its positive growth in FY 2021.

According to AMA, the Global Immuno Oncology market is expected to see growth rate of 20.3%

The Players having a strong hold in the market are F. Hoffmann-La Roche Ltd. Merck & Co., Inc Bristol-Myers Squibb Company Novartis AG Pfizer Inc.. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Immuno Oncology market throughout the predicted period.

Amgen Inc. (United States), AstraZeneca (United Kingdom), Bristol Myers Squibb (United States), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (United States), Sanofi (France), Merck KGaA (Germany), Incyte (United States) and GlaxoSmithKline plc (United Kingdom) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Eli Lilly and Company (United States), Johnson & Johnson Services, Inc. (United States), AbbVie Inc. (United States), Gilead Sciences, Inc. (United States), Aduro Biotech Inc. (United States), SELLAS Life Sciences Group Ltd (United States), Celldex Therapeutics (United States) and BeiGene (China).

Segmentation Overview
The study have segmented the market of Global Immuno Oncology market by Type (Cytokines,, Bispecific Antibodies, Cancer Vaccines, Cell Therapies, Immune Checkpoint Inhibitor and Oncolytic Viruses) and Region with country level break-up. On the basis of Type, Checkpoint Inhibitors & Immunomodulators are dominating the market in the year 2023 where as Cancer Vaccines stood as second largest market share.

On the basis of application, Hospitals segment is dominating the market in the year 2023

On the basis of geography, the market of Immuno Oncology has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). NA region held largest market share in the year 2023. Asia Pacific on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement.

Influencing Trend:
Technological Advancement Propelled by Adoption of Next Generation Cancer Treatment

Market Growth Drivers:
Growing Incidence of Cancer Across the World and Growing Healthcare Infrastructure Across Developing Regions

Challenges:
Challenges in Immuno-Oncology Trials

Restraints:
High cost

Opportunities:
Rising Investments in Development of Cancer Drugs & Treatment

Market Leaders and their Expansionary Development Strategies
In September 2020, AstraZeneca has entered into an agreement with Dogma Therapeutics to acquire its preclinical oral PCSK9 inhibitor programme. With this acquisition, it aims to take the programme forward into clinical development for dyslipidaemia, or abnormal amount of lipids in the blood, and familial hypercholesterolemia, a common genetic condition that causes high cholesterol
In January 2020, Pfizer Inc. announced the launch of its Vaccines Division’s Centers of Excellence Network, a global program of collaborations with academic institutions to conduct real-world epidemiologic research to accurately identify and measure the burden of specific vaccine-preventable diseases and potentially evaluate vaccine effectiveness affecting adults.
FDA regulates the pre-market testing and marketing approval for all immunotherapeutic agents, either as drugs or biologics depending on the source and function of the investigational agent. Immunotherapeutic products that are regulated as biologics include antibodies and proteins and some nucleic acids.

Key Target Audience
Laboratories & Research Institutes, Pharmaceutical Companies, End-Use Industries and Others

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Report Objectives / Segmentation Covered

By Type
  • Cytokines,
  • Bispecific Antibodies
  • Cancer Vaccines
  • Cell Therapies
  • Immune Checkpoint Inhibitor
  • Oncolytic Viruses
By End Users
  • Hospitals
  • Clinics
  • Others

By Therapy Type
  • Checkpoint Inhibitors & Immunomodulators
  • Cancer Vaccines
  • Oncolytic Virus
  • Others

By Therapy Area
  • Lung Cancer
  • Bladder Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Stomach Cancer
  • Liver Cancer
  • Other Cancers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Incidence of Cancer Across the World
      • 3.2.2. Growing Healthcare Infrastructure Across Developing Regions
    • 3.3. Market Challenges
      • 3.3.1. Challenges in Immuno-Oncology Trials
    • 3.4. Market Trends
      • 3.4.1. Technological Advancement Propelled by Adoption of Next Generation Cancer Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Immuno Oncology, by Type, End Users, Therapy Type, Therapy Area and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Immuno Oncology (Value)
      • 5.2.1. Global Immuno Oncology by: Type (Value)
        • 5.2.1.1. Cytokines,
        • 5.2.1.2. Bispecific Antibodies
        • 5.2.1.3. Cancer Vaccines
        • 5.2.1.4. Cell Therapies
        • 5.2.1.5. Immune Checkpoint Inhibitor
        • 5.2.1.6. Oncolytic Viruses
      • 5.2.2. Global Immuno Oncology by: End Users (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Immuno Oncology by: Therapy Type (Value)
        • 5.2.3.1. Checkpoint Inhibitors & Immunomodulators
        • 5.2.3.2. Cancer Vaccines
        • 5.2.3.3. Oncolytic Virus
        • 5.2.3.4. Others
      • 5.2.4. Global Immuno Oncology by: Therapy Area (Value)
        • 5.2.4.1. Lung Cancer
        • 5.2.4.2. Bladder Cancer
        • 5.2.4.3. Colorectal Cancer
        • 5.2.4.4. Prostate Cancer
        • 5.2.4.5. Stomach Cancer
        • 5.2.4.6. Liver Cancer
        • 5.2.4.7. Other Cancers
      • 5.2.5. Global Immuno Oncology Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Immuno Oncology: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Amgen Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bristol Myers Squibb (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck KGaA (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Incyte (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GlaxoSmithKline plc (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Immuno Oncology Sale, by Type, End Users, Therapy Type, Therapy Area and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Immuno Oncology (Value)
      • 7.2.1. Global Immuno Oncology by: Type (Value)
        • 7.2.1.1. Cytokines,
        • 7.2.1.2. Bispecific Antibodies
        • 7.2.1.3. Cancer Vaccines
        • 7.2.1.4. Cell Therapies
        • 7.2.1.5. Immune Checkpoint Inhibitor
        • 7.2.1.6. Oncolytic Viruses
      • 7.2.2. Global Immuno Oncology by: End Users (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Immuno Oncology by: Therapy Type (Value)
        • 7.2.3.1. Checkpoint Inhibitors & Immunomodulators
        • 7.2.3.2. Cancer Vaccines
        • 7.2.3.3. Oncolytic Virus
        • 7.2.3.4. Others
      • 7.2.4. Global Immuno Oncology by: Therapy Area (Value)
        • 7.2.4.1. Lung Cancer
        • 7.2.4.2. Bladder Cancer
        • 7.2.4.3. Colorectal Cancer
        • 7.2.4.4. Prostate Cancer
        • 7.2.4.5. Stomach Cancer
        • 7.2.4.6. Liver Cancer
        • 7.2.4.7. Other Cancers
      • 7.2.5. Global Immuno Oncology Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Immuno Oncology: by Type(USD Million)
  • Table 2. Immuno Oncology Cytokines, , by Region USD Million (2018-2023)
  • Table 3. Immuno Oncology Bispecific Antibodies , by Region USD Million (2018-2023)
  • Table 4. Immuno Oncology Cancer Vaccines , by Region USD Million (2018-2023)
  • Table 5. Immuno Oncology Cell Therapies , by Region USD Million (2018-2023)
  • Table 6. Immuno Oncology Immune Checkpoint Inhibitor , by Region USD Million (2018-2023)
  • Table 7. Immuno Oncology Oncolytic Viruses , by Region USD Million (2018-2023)
  • Table 8. Immuno Oncology: by End Users(USD Million)
  • Table 9. Immuno Oncology Hospitals , by Region USD Million (2018-2023)
  • Table 10. Immuno Oncology Clinics , by Region USD Million (2018-2023)
  • Table 11. Immuno Oncology Others , by Region USD Million (2018-2023)
  • Table 12. Immuno Oncology: by Therapy Type(USD Million)
  • Table 13. Immuno Oncology Checkpoint Inhibitors & Immunomodulators , by Region USD Million (2018-2023)
  • Table 14. Immuno Oncology Cancer Vaccines , by Region USD Million (2018-2023)
  • Table 15. Immuno Oncology Oncolytic Virus , by Region USD Million (2018-2023)
  • Table 16. Immuno Oncology Others , by Region USD Million (2018-2023)
  • Table 17. Immuno Oncology: by Therapy Area(USD Million)
  • Table 18. Immuno Oncology Lung Cancer , by Region USD Million (2018-2023)
  • Table 19. Immuno Oncology Bladder Cancer , by Region USD Million (2018-2023)
  • Table 20. Immuno Oncology Colorectal Cancer , by Region USD Million (2018-2023)
  • Table 21. Immuno Oncology Prostate Cancer , by Region USD Million (2018-2023)
  • Table 22. Immuno Oncology Stomach Cancer , by Region USD Million (2018-2023)
  • Table 23. Immuno Oncology Liver Cancer , by Region USD Million (2018-2023)
  • Table 24. Immuno Oncology Other Cancers , by Region USD Million (2018-2023)
  • Table 25. South America Immuno Oncology, by Country USD Million (2018-2023)
  • Table 26. South America Immuno Oncology, by Type USD Million (2018-2023)
  • Table 27. South America Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 28. South America Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 29. South America Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 30. Brazil Immuno Oncology, by Type USD Million (2018-2023)
  • Table 31. Brazil Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 32. Brazil Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 33. Brazil Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 34. Argentina Immuno Oncology, by Type USD Million (2018-2023)
  • Table 35. Argentina Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 36. Argentina Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 37. Argentina Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 38. Rest of South America Immuno Oncology, by Type USD Million (2018-2023)
  • Table 39. Rest of South America Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 40. Rest of South America Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 41. Rest of South America Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 42. Asia Pacific Immuno Oncology, by Country USD Million (2018-2023)
  • Table 43. Asia Pacific Immuno Oncology, by Type USD Million (2018-2023)
  • Table 44. Asia Pacific Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 45. Asia Pacific Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 46. Asia Pacific Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 47. China Immuno Oncology, by Type USD Million (2018-2023)
  • Table 48. China Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 49. China Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 50. China Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 51. Japan Immuno Oncology, by Type USD Million (2018-2023)
  • Table 52. Japan Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 53. Japan Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 54. Japan Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 55. India Immuno Oncology, by Type USD Million (2018-2023)
  • Table 56. India Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 57. India Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 58. India Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 59. South Korea Immuno Oncology, by Type USD Million (2018-2023)
  • Table 60. South Korea Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 61. South Korea Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 62. South Korea Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 63. Taiwan Immuno Oncology, by Type USD Million (2018-2023)
  • Table 64. Taiwan Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 65. Taiwan Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 66. Taiwan Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 67. Australia Immuno Oncology, by Type USD Million (2018-2023)
  • Table 68. Australia Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 69. Australia Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 70. Australia Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 71. Rest of Asia-Pacific Immuno Oncology, by Type USD Million (2018-2023)
  • Table 72. Rest of Asia-Pacific Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 73. Rest of Asia-Pacific Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 74. Rest of Asia-Pacific Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 75. Europe Immuno Oncology, by Country USD Million (2018-2023)
  • Table 76. Europe Immuno Oncology, by Type USD Million (2018-2023)
  • Table 77. Europe Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 78. Europe Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 79. Europe Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 80. Germany Immuno Oncology, by Type USD Million (2018-2023)
  • Table 81. Germany Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 82. Germany Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 83. Germany Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 84. France Immuno Oncology, by Type USD Million (2018-2023)
  • Table 85. France Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 86. France Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 87. France Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 88. Italy Immuno Oncology, by Type USD Million (2018-2023)
  • Table 89. Italy Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 90. Italy Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 91. Italy Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 92. United Kingdom Immuno Oncology, by Type USD Million (2018-2023)
  • Table 93. United Kingdom Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 94. United Kingdom Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 95. United Kingdom Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 96. Netherlands Immuno Oncology, by Type USD Million (2018-2023)
  • Table 97. Netherlands Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 98. Netherlands Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 99. Netherlands Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 100. Rest of Europe Immuno Oncology, by Type USD Million (2018-2023)
  • Table 101. Rest of Europe Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 102. Rest of Europe Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 103. Rest of Europe Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 104. MEA Immuno Oncology, by Country USD Million (2018-2023)
  • Table 105. MEA Immuno Oncology, by Type USD Million (2018-2023)
  • Table 106. MEA Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 107. MEA Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 108. MEA Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 109. Middle East Immuno Oncology, by Type USD Million (2018-2023)
  • Table 110. Middle East Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 111. Middle East Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 112. Middle East Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 113. Africa Immuno Oncology, by Type USD Million (2018-2023)
  • Table 114. Africa Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 115. Africa Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 116. Africa Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 117. North America Immuno Oncology, by Country USD Million (2018-2023)
  • Table 118. North America Immuno Oncology, by Type USD Million (2018-2023)
  • Table 119. North America Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 120. North America Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 121. North America Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 122. United States Immuno Oncology, by Type USD Million (2018-2023)
  • Table 123. United States Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 124. United States Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 125. United States Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 126. Canada Immuno Oncology, by Type USD Million (2018-2023)
  • Table 127. Canada Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 128. Canada Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 129. Canada Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 130. Mexico Immuno Oncology, by Type USD Million (2018-2023)
  • Table 131. Mexico Immuno Oncology, by End Users USD Million (2018-2023)
  • Table 132. Mexico Immuno Oncology, by Therapy Type USD Million (2018-2023)
  • Table 133. Mexico Immuno Oncology, by Therapy Area USD Million (2018-2023)
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Immuno Oncology: by Type(USD Million)
  • Table 145. Immuno Oncology Cytokines, , by Region USD Million (2025-2030)
  • Table 146. Immuno Oncology Bispecific Antibodies , by Region USD Million (2025-2030)
  • Table 147. Immuno Oncology Cancer Vaccines , by Region USD Million (2025-2030)
  • Table 148. Immuno Oncology Cell Therapies , by Region USD Million (2025-2030)
  • Table 149. Immuno Oncology Immune Checkpoint Inhibitor , by Region USD Million (2025-2030)
  • Table 150. Immuno Oncology Oncolytic Viruses , by Region USD Million (2025-2030)
  • Table 151. Immuno Oncology: by End Users(USD Million)
  • Table 152. Immuno Oncology Hospitals , by Region USD Million (2025-2030)
  • Table 153. Immuno Oncology Clinics , by Region USD Million (2025-2030)
  • Table 154. Immuno Oncology Others , by Region USD Million (2025-2030)
  • Table 155. Immuno Oncology: by Therapy Type(USD Million)
  • Table 156. Immuno Oncology Checkpoint Inhibitors & Immunomodulators , by Region USD Million (2025-2030)
  • Table 157. Immuno Oncology Cancer Vaccines , by Region USD Million (2025-2030)
  • Table 158. Immuno Oncology Oncolytic Virus , by Region USD Million (2025-2030)
  • Table 159. Immuno Oncology Others , by Region USD Million (2025-2030)
  • Table 160. Immuno Oncology: by Therapy Area(USD Million)
  • Table 161. Immuno Oncology Lung Cancer , by Region USD Million (2025-2030)
  • Table 162. Immuno Oncology Bladder Cancer , by Region USD Million (2025-2030)
  • Table 163. Immuno Oncology Colorectal Cancer , by Region USD Million (2025-2030)
  • Table 164. Immuno Oncology Prostate Cancer , by Region USD Million (2025-2030)
  • Table 165. Immuno Oncology Stomach Cancer , by Region USD Million (2025-2030)
  • Table 166. Immuno Oncology Liver Cancer , by Region USD Million (2025-2030)
  • Table 167. Immuno Oncology Other Cancers , by Region USD Million (2025-2030)
  • Table 168. South America Immuno Oncology, by Country USD Million (2025-2030)
  • Table 169. South America Immuno Oncology, by Type USD Million (2025-2030)
  • Table 170. South America Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 171. South America Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 172. South America Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 173. Brazil Immuno Oncology, by Type USD Million (2025-2030)
  • Table 174. Brazil Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 175. Brazil Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 176. Brazil Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 177. Argentina Immuno Oncology, by Type USD Million (2025-2030)
  • Table 178. Argentina Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 179. Argentina Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 180. Argentina Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 181. Rest of South America Immuno Oncology, by Type USD Million (2025-2030)
  • Table 182. Rest of South America Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 183. Rest of South America Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 184. Rest of South America Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 185. Asia Pacific Immuno Oncology, by Country USD Million (2025-2030)
  • Table 186. Asia Pacific Immuno Oncology, by Type USD Million (2025-2030)
  • Table 187. Asia Pacific Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 188. Asia Pacific Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 189. Asia Pacific Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 190. China Immuno Oncology, by Type USD Million (2025-2030)
  • Table 191. China Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 192. China Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 193. China Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 194. Japan Immuno Oncology, by Type USD Million (2025-2030)
  • Table 195. Japan Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 196. Japan Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 197. Japan Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 198. India Immuno Oncology, by Type USD Million (2025-2030)
  • Table 199. India Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 200. India Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 201. India Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 202. South Korea Immuno Oncology, by Type USD Million (2025-2030)
  • Table 203. South Korea Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 204. South Korea Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 205. South Korea Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 206. Taiwan Immuno Oncology, by Type USD Million (2025-2030)
  • Table 207. Taiwan Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 208. Taiwan Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 209. Taiwan Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 210. Australia Immuno Oncology, by Type USD Million (2025-2030)
  • Table 211. Australia Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 212. Australia Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 213. Australia Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 214. Rest of Asia-Pacific Immuno Oncology, by Type USD Million (2025-2030)
  • Table 215. Rest of Asia-Pacific Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 216. Rest of Asia-Pacific Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 217. Rest of Asia-Pacific Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 218. Europe Immuno Oncology, by Country USD Million (2025-2030)
  • Table 219. Europe Immuno Oncology, by Type USD Million (2025-2030)
  • Table 220. Europe Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 221. Europe Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 222. Europe Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 223. Germany Immuno Oncology, by Type USD Million (2025-2030)
  • Table 224. Germany Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 225. Germany Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 226. Germany Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 227. France Immuno Oncology, by Type USD Million (2025-2030)
  • Table 228. France Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 229. France Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 230. France Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 231. Italy Immuno Oncology, by Type USD Million (2025-2030)
  • Table 232. Italy Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 233. Italy Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 234. Italy Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 235. United Kingdom Immuno Oncology, by Type USD Million (2025-2030)
  • Table 236. United Kingdom Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 237. United Kingdom Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 238. United Kingdom Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 239. Netherlands Immuno Oncology, by Type USD Million (2025-2030)
  • Table 240. Netherlands Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 241. Netherlands Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 242. Netherlands Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 243. Rest of Europe Immuno Oncology, by Type USD Million (2025-2030)
  • Table 244. Rest of Europe Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 245. Rest of Europe Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 246. Rest of Europe Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 247. MEA Immuno Oncology, by Country USD Million (2025-2030)
  • Table 248. MEA Immuno Oncology, by Type USD Million (2025-2030)
  • Table 249. MEA Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 250. MEA Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 251. MEA Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 252. Middle East Immuno Oncology, by Type USD Million (2025-2030)
  • Table 253. Middle East Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 254. Middle East Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 255. Middle East Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 256. Africa Immuno Oncology, by Type USD Million (2025-2030)
  • Table 257. Africa Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 258. Africa Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 259. Africa Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 260. North America Immuno Oncology, by Country USD Million (2025-2030)
  • Table 261. North America Immuno Oncology, by Type USD Million (2025-2030)
  • Table 262. North America Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 263. North America Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 264. North America Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 265. United States Immuno Oncology, by Type USD Million (2025-2030)
  • Table 266. United States Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 267. United States Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 268. United States Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 269. Canada Immuno Oncology, by Type USD Million (2025-2030)
  • Table 270. Canada Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 271. Canada Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 272. Canada Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 273. Mexico Immuno Oncology, by Type USD Million (2025-2030)
  • Table 274. Mexico Immuno Oncology, by End Users USD Million (2025-2030)
  • Table 275. Mexico Immuno Oncology, by Therapy Type USD Million (2025-2030)
  • Table 276. Mexico Immuno Oncology, by Therapy Area USD Million (2025-2030)
  • Table 277. Research Programs/Design for This Report
  • Table 278. Key Data Information from Secondary Sources
  • Table 279. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Immuno Oncology: by Type USD Million (2018-2023)
  • Figure 5. Global Immuno Oncology: by End Users USD Million (2018-2023)
  • Figure 6. Global Immuno Oncology: by Therapy Type USD Million (2018-2023)
  • Figure 7. Global Immuno Oncology: by Therapy Area USD Million (2018-2023)
  • Figure 8. South America Immuno Oncology Share (%), by Country
  • Figure 9. Asia Pacific Immuno Oncology Share (%), by Country
  • Figure 10. Europe Immuno Oncology Share (%), by Country
  • Figure 11. MEA Immuno Oncology Share (%), by Country
  • Figure 12. North America Immuno Oncology Share (%), by Country
  • Figure 13. Global Immuno Oncology share by Players 2023 (%)
  • Figure 14. Global Immuno Oncology share by Players (Top 3) 2023(%)
  • Figure 15. Global Immuno Oncology share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Amgen Inc. (United States) Revenue: by Geography 2023
  • Figure 19. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 21. Bristol Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 22. Bristol Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 23. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2023
  • Figure 25. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 27. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 29. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi (France) Revenue: by Geography 2023
  • Figure 31. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Merck KGaA (Germany) Revenue: by Geography 2023
  • Figure 33. Incyte (United States) Revenue, Net Income and Gross profit
  • Figure 34. Incyte (United States) Revenue: by Geography 2023
  • Figure 35. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 37. Global Immuno Oncology: by Type USD Million (2025-2030)
  • Figure 38. Global Immuno Oncology: by End Users USD Million (2025-2030)
  • Figure 39. Global Immuno Oncology: by Therapy Type USD Million (2025-2030)
  • Figure 40. Global Immuno Oncology: by Therapy Area USD Million (2025-2030)
  • Figure 41. South America Immuno Oncology Share (%), by Country
  • Figure 42. Asia Pacific Immuno Oncology Share (%), by Country
  • Figure 43. Europe Immuno Oncology Share (%), by Country
  • Figure 44. MEA Immuno Oncology Share (%), by Country
  • Figure 45. North America Immuno Oncology Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Amgen Inc. (United States)
  • AstraZeneca (United Kingdom)
  • Bristol Myers Squibb (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (United States)
  • Sanofi (France)
  • Merck KGaA (Germany)
  • Incyte (United States)
  • GlaxoSmithKline plc (United Kingdom)
Additional players considered in the study are as follows:
Eli Lilly and Company (United States) , Johnson & Johnson Services, Inc. (United States) , AbbVie Inc. (United States) , Gilead Sciences, Inc. (United States) , Aduro Biotech Inc. (United States) , SELLAS Life Sciences Group Ltd (United States) , Celldex Therapeutics (United States) , BeiGene (China)
Select User Access Type

Key Highlights of Report


Mar 2024 147 Pages 73 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Immuno Oncology Market Quantitative research analysis
Global Immuno Oncology Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Immuno Oncology study can be customized to meet your requirements. The market size breakdown by type, by end-use application.
The Immuno Oncology Market is gaining popularity and expected to see strong valuation by 2030 .
According to AMA, the Global Immuno Oncology market is expected to see growth rate of xx%.
The Immuno Oncology market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Immuno Oncology Market Report?

Have a Query? Click Here

Other Related Reports

Hemato Oncology Testing Comprehensive Study by Type (Leukemia, Lymphoma, Myeloproliferative Neoplasms, Others), Application (Assay Kits and Reagents, Services), Technology (PCR, HIS, NGS, Cytogenetic...
$ 3450
Bone Fracture Comprehensive Study by Application (Hospitals, Clinics, Orthopedic Centers, Ambulatory Surgical Centers, Others), Healing Stage (Reactive Stage, Repair Stage, Remodeling Phase), Imaging...
$ 3750
Automated blood Tube Labeler & Specimen Transport Box Comprehensive Study by Application (Hospitals, Diagnostic Centers, Blood Banks), Tubes Type (Plastic Tubes, Glass Tubes), Box Type (Traditional B...
$ 3350
Urinary-Incontinence Comprehensive Study by Type (Stress Urinary Incontinence, Urge Urinary Incontinence, Overflow Incontinence, Functional Urinary Incontinence), Application (Hospitals, Homecare, Sp...
$ 3750
Learning Disability Treatment Comprehensive Study by Type (Medication, Individualized Educational Program (IEP), Occupational Therapy, Orton–Gillingham Approach, Others), Application (ADHD, Dyslexia,...
$ 3350
Weight Monitoring System Comprehensive Study by Type (Digital Weight Monitoring Device, Analog Weight Monitoring Device), Application (Residential, Commercial), Distribution Channel (Online, Offline)...
$ 3350